Aspen Pharmacare earnings surged in its latest financial year, with normalised headline earnings per share climbing 22% on the back of booming demand for weight-loss medicines. Africa’s largest drugmaker reported the rise on Wednesday for the year ending 30 June. The standout driver was Eli Lilly’s Mounjaro, which Aspen promotes and sells across South Africa and other Sub-Saharan African markets…